PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.06%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
7.06%
Positive operating income growth while AVXL is negative. John Neff might view this as a competitive edge in operations.
10.36%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
28.30%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
28.30%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
24.68%
Share count expansion well above AVXL's 0.85%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.68%
Diluted share count expanding well above AVXL's 0.85%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
17.79%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
17.79%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19298.96%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-3628.66%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
45.61%
3Y OCF/share CAGR above 1.5x AVXL's 26.75%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-15204.15%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
97.68%
5Y net income/share CAGR 1.25-1.5x AVXL's 86.43%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
59.13%
3Y net income/share CAGR above 1.5x AVXL's 15.41%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
9892.41%
10Y equity/share CAGR above 1.5x AVXL's 700.31%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
293.35%
5Y equity/share CAGR is in line with AVXL's 282.23%. Walter Schloss would see parallel mid-term profitability and retention policies.
201.29%
Positive short-term equity growth while AVXL is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Asset growth above 1.5x AVXL's 5.51%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
64.49%
BV/share growth above 1.5x AVXL's 8.23%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
13.21%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-38.56%
We cut SG&A while AVXL invests at 25.90%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.